Research progress in immunotherapy for nonalcoholic fatty liver disease related hepatocellular carcinoma
10.3760/cma.j.cn113884-20241204-00361
- VernacularTitle:非酒精性脂肪性肝病相关肝细胞癌的免疫治疗研究进展
- Author:
Jinlong ZHOU
1
;
Junjie LIU
;
Xinrong WEI
;
Hao GU
Author Information
1. 新疆医科大学第一附属医院肝脏腹腔镜外科，乌鲁木齐 830011
- Publication Type:Journal Article
- Keywords:
Carcinoma, hepatocellular;
Non-alcoholic fatty liver disease;
Immune checkpoint inhibitors;
Tumor microenvironment
- From:
Chinese Journal of Hepatobiliary Surgery
2025;31(6):477-480
- CountryChina
- Language:Chinese
-
Abstract:
In recent years, non-alcoholic fatty liver disease (NAFLD) is the fastest growing pathogenic factor of primary liver cancer (PLC). Compared with virus-associated hepatocellular carcinoma (HCC), HCC associated with NAFLD has a unique immune microenvironment, and combined treatment with corresponding targets can improve the immunetherapeutic efficacy. However, prospective studies are still needed for the immunotherapy response of different causes of PLC is different and the therapeutic efficacy has not reached consensus. The high-level evidence of etiology stratification, personalized precision immunotherapy and combinational therapy may be the future milestones in this area. We hereby reviews the epidemiology, tumor microenvironment, and immunotherapy of NAFLD-related HCC.
